Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash from Financing Activities (2016 - 2025)

Angiodynamics (ANGO) has disclosed Cash from Financing Activities for 16 consecutive years, with -$92000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 91.81% year-over-year to -$92000.0, compared with a TTM value of $1.4 million through Nov 2025, up 124.05%, and an annual FY2025 reading of -$255000.0, up 99.6% over the prior year.
  • Cash from Financing Activities was -$92000.0 for Q4 2025 at Angiodynamics, down from $143000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $24.4 million in Q3 2022 and bottomed at -$59.6 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is -$2.6 million, with a median of $103000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities soared 9520.0% in 2021, then plummeted 441.75% in 2023.
  • Year by year, Cash from Financing Activities stood at $942000.0 in 2021, then plummeted by 89.07% to $103000.0 in 2022, then tumbled by 441.75% to -$352000.0 in 2023, then crashed by 219.03% to -$1.1 million in 2024, then skyrocketed by 91.81% to -$92000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for ANGO at -$92000.0 in Q4 2025, $143000.0 in Q3 2025, and -$5.8 million in Q2 2025.